Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis.

Pietro Lampertico,Jose A Carrión,Michael Curry,Juan Turnes,Markus Cornberg,Francesco Negro,Ashley Brown,Marcello Persico,Nicole Wick,Ariel Porcalla,Andreas Pangerl,Eric Crown,Lois Larsen,Yao Yu, Heiner Wedemeyer

Journal of Hepatology（2020）

引用 56|浏览68

暂无评分

摘要

•Meta-analysis of real-world data from 12,583 patients taking glecaprevir/pibrentasvir.•Glecaprevir/pibrentasvir achieved 96.7% virologic cure overall.•Virologic cure was ≥95% across subgroups of interest.•Serious adverse events were reported in 1.0% of patients.•Effectiveness and safety results were consistent with those from clinical trials.

查看译文

关键词

Hepatitis C virus,Meta-analysis,Clinical practice,Pangenotypic,On-label

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要